Biglycan expression in hypertensive subjects with normal or increased carotid intima-media wall thickness

Clinica Chimica Acta

Volumn 406, Issue 1-2, 2009, Pages 89-93

  Sardo, Maria Adriana ^a   Mandraffino, Giuseppe ^a   Campo, Salvatore ^a   Saitta, Carlo ^a   Bitto, Alessandra ^b   Alibrandi, Angela ^a   Riggio, Stefania ^a   Imbalzano, Egidio ^a   Saitta, Antonino ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Angiotensin II; Arterial hypertension; Atherosclerosis; Biglycan; Carotid intima media thickness; Inflammation; Monocytes

Indexed keywords

ANGIOTENSIN II; BIGLYCAN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CELL ISOLATION; CONTROLLED STUDY; DISEASE CLASSIFICATION; ESSENTIAL HYPERTENSION; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MONOCYTE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RISK FACTOR; WESTERN BLOTTING;

ADULT; ANGIOTENSIN II; C-REACTIVE PROTEIN; CAROTID ARTERIES; CASE-CONTROL STUDIES; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYPERTENSION; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES; MALE; MONOCYTES; PROTEOGLYCANS; REGRESSION ANALYSIS; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; TUNICA INTIMA;

EID: 67650217506     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2009.05.024     Document Type: Article

References (41)

1. Ameye L., Aria D., Jepsen K., Oldberg A., Xu T., and Young M.F. Abnormal collagen fibrils in tendons of biglycan/fibromodulin-deficient mice lead to gait impairment, ectopic ossification, and osteoarthritis. FASEB J 16 (2002) 673-680
2. Nakashima Y., Wight T.N., and Sueishi K. Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans. Cardiovasc Res 79 (2008) 14-23
3. Williams K.J., and Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol 15 (1995) 551-561
4. Little P.J., Osman N., and O'Brien K.D. Hyperelongated biglycan: the surreptitious initiator of atherosclerosis. Curr Opin Lipidol 19 (2008) 448-454
5. Couchman J.R., Austria M.R., and Woods A. Fibronectin-cell interactions. Invest Dermatol 94 (1990) 7S-14S
6. Hildebrand A., Romarís M., Rasmussen L.M., et al. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor. Biochem J 302 (1994) 527-534
7. Tufvesson E., and Westergren-Thorsson G. Tumour necrosis factor-alpha interacts with biglycan and decorin. FEBS 530 (2002) 124-128
8. Chieppa M., Bianchi G., Doni A., et al. Cross-linking of the mannose receptor on monocyte-derived dendritic cells activates an anti-inflammatory immunosuppressive program. J Immunol 171 (2003) 4552-4560
9. Schaefer L., Babelova A., Kiss E., Hausser H.J., Baliova M., and Krzyzankova M. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 115 (2005) 2223-2233
10. Dörffel Y., Lätsch C., Stuhlmüller B., et al. Preactivated peripheral blood monocytes in patients with essential hypertension. Hypertension 34 (1999) 113-117
11. Bautista L.E., Vera L.M., Arenas I.A., and Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-alpha) and essential hypertension. Hum Hypertens 19 (2005) 149-154
12. Kim K.I., Lee J.H., Chang H.J., et al. Association between blood pressure variability and inflammatory marker in hypertensive patients. Circ J 72 (2008) 293-298
13. Naya M., Tsukamoto T., Morita K., et al. Plasma interleukin-6 and tumor necrosis factor-alpha can predict coronary endothelial dysfunction in hypertensive patients. Hypertens Res 30 (2007) 541-548
14. Sardo M.A., Campo S., Castaldo M., et al. Tissue factor expression and activity are not increased in peripheral monocytes isolated from uncomplicated hypertensive patients. J Hypertens 24 (2006) 731-736
15. Gabay C., and Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340 (1999) 448-454
16. Hansson G.K. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 21 (2001) 1876-1890
17. Papanicolaou D.A., and Vgontzas A.N. Interleukin-6: the endocrine cytokine. J Clin Endocrinol Metab 85 (2000) 1331-1333
18. Yudkin J.S., Kumari M., Humphries S.E., and Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis 148 (2000) 209-214
19. Lee D.L., Sturgis L.C., Labazi H., et al. Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am J Physiol Heart Circ Physiol 290 (2006) H935-H940
20. Mackay F., Loetscher H., Stueber D., Gehr G., and Lesslauer W. Tumor necrosis factor alpha (TNF-alpha)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J Exp Med 177 (1993) 1277-1286
21. Tartaglia L.A., Ayres T.M., Wong G.H., and Goeddel D.V. A novel domain within the 55 kd TNF receptor signals cell death. Cell 74 (1993) 845-853
22. Pfeffer K., Matsuyama T., Kündig T.M., et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73 (1993) 457-467
23. Leibowitz D., Planer D., Ben-Ivgi F., Weiss A.T., and Bursztyn M. Tumor necrosis factor and interleukin-6 levels in hypertensive patients with and without left ventricular hypertrophy. Blood Press 14 (2005) 21-24
24. Zhang H., Park Y., Wu J., Chen X., Lee S., and Yang J. Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond) 116 (2009) 219-230
25. Pasceri V., Willerson J.T., and Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102 (2000) 2165-2168
26. Wang C.H., Li S.H., Weisel R.D., et al. C-reactive protein upregulates Angiotensin type 1 receptors in vascular smooth muscle. Circulation 107 (2003) 1783-1790
27. Sesso H.D., Wang L., Buring J.E., Ridker P.M., and Gaziano J.M. Comparison of interleukin-6 and C-reactive protein for the risk of developing hypertension in women. Hypertension 49 (2007) 304-310
28. Zacho J., Tybjaerg-Hansen A., Jensen J.S., Grande P., Sillesen H., and Nordestgaard B.G. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med 30 (2008) 1897-1908
29. Kivimäki M., Lawlor D.A., Eklund C., et al. Mendelian randomization suggests no causal association between C-reactive protein and carotid intima-media thickness in the young Finns study. Arterioscler Thromb Vasc Biol 27 (2007) 978-979
30. Nolan T., Hands R.E., and Bustin S.A. Quantification of mRNA using real-time RT-PCR. Nat Protoc 1 (2006) 1559-1582
31. Schaefer L., Macakova K., Raslik I., et al. Absence of decorin adversely influences tubulointerstitial fibrosis of the obstructed kidney by enhanced apoptosis and increased inflammatory reaction. Am J Pathol 160 (2002) 1181-1191
32. Alimohamad H., Habijanac T., Larjava H., and Häkkinen L. Colocalization of the collagen-binding proteoglycans decorin, biglycan, fibromodulin and lumican with different cells in human gingiva. J Periodontal Res 40 (2005) 73-86
33. Hahn A.W., Jonas U., Bühler F.R., and Resink T.J. Activation of human peripheral monocytes by angiotensin II. FEBS Lett 347 (1994) 178-180
34. Tiede K., Stöter K., Petrik C., et al. Angiotensin II AT(1)-receptor induces biglycan in neonatal cardiac fibroblasts via autocrine release of TGF-beta in vitro. Cardiovasc Res 60 (2003) 538-546
35. Huang F., Thompson J.C., Wilson P.G., Aung H.H., Rutledge J.C., and Tannock L.R. Angiotensin II increases vascular proteolycan content preceding and contributing to atherosclerosis development. J Lipid Res 49 (2008) 521-530
36. Figueroa J.E., and Vijayagopal P. Angiotensin II stimulates synthesis of vascular smooth muscle cell proteoglycans with enhanced low density lipoprotein binding properties. Atherosclerosis 162 (2002) 261-268
37. Nagata K., Ishibashi T., Sakamoto T., et al. Effects of blockade of the renin-angiotensin system on tissue factor and plasminogen activator inhibitor-1 synthesis in human cultured monocytes. J Hypertens 19 (2001) 775-783
38. Castro C.M., Cruzado M.C., Miatello R.M., and Risler N.R. Proteoglycan production by vascular smooth muscle cells from resistance arteries of hypertensive rats. Hypertension 34 (1999) 893-896
39. Dasu M.R., Riosvelasco A.C., and Jialal I. Candesartan inhibits Toll-like receptor expression and activity both in vitro and in vivo. Atherosclerosis 202 (2009) 76-83
40. Kähäri V.M., Larjava H., and Uitto J. Differential regulation of extracellular matrix proteoglycan (PG) gene expression. Transforming growth factor-beta 1 up-regulates biglycan (PGI), and versican (large fibroblast PG) but down-regulates decorin (PGII) mRNA levels in human fibroblasts in culture. 1. J Biol Chem 266 (1991) 10608-10615
41. Tiedemann K., Malmström A., and Westergren-Thorsson G. Cytokine regulation of proteoglycan production in fibroblasts: separate and synergistic effects. Matrix Biol 15 (1997) 469-478